BICD1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Jurkat human T lymphocyte cell line. This product consists of a mixed population of cells harboring targeted disruptions at the BICD1 locus, providing a robust loss-of-function model that avoids the clonal artifacts associated with single-cell-derived knockouts. The polyclonal format preserves genetic background diversity, making it particularly suitable for studies where population-level responses are critical, such as signaling dynamics and drug sensitivity profiling.
The Jurkat host cell line, derived from an acute T cell leukemia patient, is a CD4+ T lymphocyte model extensively used for dissecting T cell receptor (TCR) signaling, interleukin-2 production, and apoptotic pathways. Its leukemic origin also renders it an invaluable tool for investigating oncogenic signaling networks and therapeutic resistance mechanisms in T cell malignancies. The cells grow in suspension and are amenable to a wide range of genetic manipulations and functional assays.
BICD1 encodes a coiled-coil adaptor protein that recruits diverse cargos to the dynein?Cdynactin motor complex for retrograde transport along microtubules. It directly binds the dynein heavy chain DYNC1H1 and the dynactin subunit DCTN2, and its cargo specificity is modulated through interactions with the small GTPase RAB6A and the Golgi-associated protein GOLGA4. Activation of Rab6 and PKC signaling pathways promotes BICD1-mediated transport. Downstream, BICD1 regulates the minus-end-directed movement of endosomes, lysosomes, and other vesicles, as well as centrosome and nuclear positioning. Consequently, disruption of BICD1 impairs intracellular trafficking, organelle distribution, and the spatial organization of signaling molecules.
In Jurkat T cells, efficient retrograde transport is critical for maintaining the architecture of the immune synapse and for the rapid endosomal recycling of TCR components upon activation. BICD1 loss can therefore perturb TCR-induced signaling cascades, cytokine secretion, and actin cytoskeleton remodeling. Furthermore, disrupted organelle positioning may affect cell cycle progression and directional migration, processes that are often dysregulated in leukemic cells. This model also provides a relevant context for exploring how dynein adaptors influence the intracellular trafficking of viruses like HIV-1, which exploits host transport machinery for replication.
Researchers can apply these polyclonal knockout cells in diverse experimental paradigms. Protein blotting and immunofluorescence microscopy allow verification of BICD1 ablation and visualization of endosome and organelle mislocalization. Co-immunoprecipitation experiments enable assessment of altered dynein complex assembly. Functional readouts include live-cell imaging to track endosome motility, flow cytometry for cell cycle analysis, and Transwell assays for chemotactic migration. Moreover, the model is adaptable for high-throughput screens searching for retrograde transport modulators and for testing sensitivity to microtubule-targeting chemotherapeutics such as vinca alkaloids and taxanes. For further details or customized inquiries, please reach out to Ascent Research.
